Swedish Orphan Biovitrum AB (publ) Overview
Pro stress-test →Sobi is an international specialty healthcare company dedicated to rare diseases with a focus on treatments in haematology, immunology and speciality care. The company commands a strong market position with market capitalization of $15.5B and operates across multiple therapeutic areas addressing significant unmet medical needs in orphan diseases.
Strategic Profile
Pro stress-test →Sobi is an integrated biopharmaceutical company with capabilities throughout the value chain and a strong track record of commercializing medications in complex markets. Sobi was able to achieve reimbursement across its European markets by an average of 4.9 months faster than is standard. The company leverages deep patient access expertise and established distribution capabilities to rapidly bring rare disease treatments to market.
Competitive Landscape
Pro stress-test →Competitors include Novo Nordisk, BioMarin Pharmaceutical, United Therapeutics, Gilead, and Genzyme Ireland. Sobi differentiates through deep expertise in rare disease commercialization, integrated capabilities from development to patient access, and strong European market presence, though faces competition from larger pharma companies and specialized biotechs.
Industry Context
Swedish Orphan Biovitrum AB (publ) operates in Specialty Biopharmaceuticals - Rare Diseases.
Key facts
Founded: 2010 · Headquarters: Stockholm, Sweden · Employees: 1,890 · Revenue: $2.87B · Market cap: $15.5B